TP53 and lung adenocarcinoma: The current study evaluating a large real-world population of lung adenocarcinoma patients confirms and generalises the predictive impact of KRAS/TP53 co-mutation than was reported in two earlier studies in a more specific patient population especially for KRAS G12C mutations [12, 13].